Mechanistic description
Develop non-invasive imaging or CSF biomarkers to quantify individual FcRn expression/activity at the BBB. Patients with different FcRn activity levels would receive adjusted dosing.
Debate provenance: derived from debate sess_SDA-2026-04-12-gap-debate-20260410-112908-13c403ee on question: What is the actual quantitative contribution of FcRn-mediated transcytosis to BBB antibody transport in humans?. Consensus signal: domain_expert, medicinal_chemist, skeptic, synthesizer, theorist discussed the mechanism terms BBB, Biomarker-Guided, CSF, Dosing, Expression, FCGRT. Novelty signal: skeptic-discussed-counterarguments.
Evidence for (1)
Evidence matrix
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). FcRn Expression Biomarker-Guided Dosing. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-debate-e0d69bf9bc48
@misc{scidex_hypothesis_hdebatee,
title = {FcRn Expression Biomarker-Guided Dosing},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-debate-e0d69bf9bc48},
note = {SciDEX artifact hypothesis:h-debate-e0d69bf9bc48}
}